
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This publication is sponsored by Acadia Pharmaceuticals, Inc.
This Clinical Brief explores the prevalence and burden associated with dementia-related psychosis, underscoring a critical unmet need for effective therapy.






